PMID- 25371055
OWN - NLM
STAT- MEDLINE
DCOM- 20150122
LR  - 20221207
IS  - 0391-1977 (Print)
IS  - 0391-1977 (Linking)
VI  - 39
IP  - 4
DP  - 2014 Dec
TI  - Multiple drug combination of anti-diabetic agents as a predictor for poor 
      clinical response to liraglutide.
PG  - 289-97
AB  - AIM: Aim of the study was to retrospectively analyze the clinical parameters that 
      contribute to the therapeutic outcome of GLP-1 analogues. METHODS: We enrolled 
      106 patients with type 2 diabetes mellitus (T2DM), treated with liraglutide 
      (N.=69) or exenatide (N.=37) for longer than three months. The patients were 
      divided into two groups: good responders and poor responders to GLP-1 analogues, 
      based on pretreatment and post-treatment HbA1c levels. Good responders were those 
      whose HbA1c level had decreased by 1% or more, or maintained at less than 7%. All 
      other patients were categorized as poor responders. We used univariate and 
      multivariate analyses to assess pretreatment parameters between the two groups. 
      RESULTS: Approximately 35% of the patients were poor responders. Our analysis of 
      the pretreatment clinical parameters revealed that number of anti-diabetic agents 
      and use of sulfonylurea were significantly associated with poor response to 
      liraglutide (P=0.02 and P=0.03, respectively) in a multivariate analysis. We were 
      not able to find any candidate related to clinical response to exenatide. 
      CONCLUSION: Our study showed that the therapeutic effects of GLP-1 analogues on 
      T2DM patients were heterogeneous. T2DM patients who require multiple 
      anti-diabetic agents, especially sulfonylurea, do not benefit from liraglutide 
      treatment.
FAU - Haraguchi, A
AU  - Haraguchi A
AD  - Division of Endocrinology and Metabolism Nagasaki University Graduate School of 
      Biomedical Sciences, Nagasaki, Japan - takaoando@gmail.com.
FAU - Fujishima, K
AU  - Fujishima K
FAU - Ando, T
AU  - Ando T
FAU - Mori, F
AU  - Mori F
FAU - Imaizumi, M
AU  - Imaizumi M
FAU - Abiru, N
AU  - Abiru N
FAU - Yamasaki, H
AU  - Yamasaki H
FAU - Matsumoto, K
AU  - Matsumoto K
FAU - Takamura, N
AU  - Takamura N
FAU - Kawakami, A
AU  - Kawakami A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - Minerva Endocrinol
JT  - Minerva endocrinologica
JID - 8406505
RN  - 0 (Biguanides)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Peptides)
RN  - 0 (Sulfonylurea Compounds)
RN  - 0 (Thiazolidines)
RN  - 0 (Venoms)
RN  - 839I73S42A (Liraglutide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9P1872D4OL (Exenatide)
RN  - EC 2.6.1.2 (Alanine Transaminase)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Alanine Transaminase/blood
MH  - Anthropometry
MH  - Biguanides/administration & dosage/therapeutic use
MH  - Body Weight/drug effects
MH  - Comorbidity
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Drug Therapy, Combination
MH  - Exenatide
MH  - Female
MH  - Glucagon-Like Peptide 1/administration & dosage/*analogs & 
      derivatives/therapeutic use
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/*therapeutic use
MH  - Insulin/administration & dosage/metabolism/therapeutic use
MH  - Insulin Secretion
MH  - Liraglutide
MH  - Male
MH  - Middle Aged
MH  - Peptides/administration & dosage/*therapeutic use
MH  - Prognosis
MH  - Retrospective Studies
MH  - Sulfonylurea Compounds/administration & dosage/therapeutic use
MH  - Thiazolidines/administration & dosage/therapeutic use
MH  - Treatment Outcome
MH  - Venoms/administration & dosage/*therapeutic use
EDAT- 2014/11/06 06:00
MHDA- 2015/01/23 06:00
CRDT- 2014/11/06 06:00
PHST- 2014/11/06 06:00 [entrez]
PHST- 2014/11/06 06:00 [pubmed]
PHST- 2015/01/23 06:00 [medline]
AID - R07Y2014N04A0289 [pii]
PST - ppublish
SO  - Minerva Endocrinol. 2014 Dec;39(4):289-97.